Tuberculin conversion and leukocyte migration inhibition test after BCG vaccination in newborn infants

Mma Faridi1, Sarvpreet Kaur, Sriram Krishnamurthy

  • 1Division of Neonatology, Department of Pediatrics, University College of Medical Sciences, University of Delhi and Guru Tegh Bahadur Hospital, New Delhi, India. drmmafaridi@gmail.com

Human Vaccines
|October 27, 2009
PubMed

Insights

BCG vaccination is effective in preterm and low birth weight infants, but tuberculin conversion is an unreliable indicator of immune response. Local BCG reactions at 8 weeks better reflect cell-mediated immunity.

Area of Science:

  • Immunology
  • Pediatrics
  • Vaccinology

Background:

  • Reports suggest suboptimal BCG vaccine uptake in preterm and low birth weight neonates.
  • Assessing BCG vaccine efficacy in vulnerable infant populations is crucial for global tuberculosis control.

Purpose of the Study:

  • To evaluate BCG vaccine take-up via tuberculin conversion using the Mantoux test at 12 weeks and 6 months.
  • To assess the utility of the Leukocyte Migration Inhibition Test (LMIT) in BCG-vaccinated infants with negative Mantoux tests.

Main Methods:

  • A prospective observational study involving 143 neonates (31-41 weeks gestation) vaccinated with BCG within 7 days of birth.
  • Mantoux testing at 12 weeks and 6 months, with LMIT performed on Mantoux-negative infants.
  • Follow-up included repeat Mantoux and LMIT tests to assess immune response over time.

Main Results:

  • 95.5% of infants showed local BCG reactions at 8 weeks; 47.2% developed scars by 12 weeks.
  • Tuberculin conversion rates were 42.7% at 12 weeks and increased to 66.4% by 6 months.
  • LMIT was positive in 84.1% of Mantoux-negative infants at 12 weeks, indicating cellular immunity.

Conclusions:

  • BCG vaccination is effective in preterm (31-36 weeks) and low birth weight (<2500g) infants.
  • Tuberculin conversion is not a reliable sole indicator of BCG vaccine response.
  • Local BCG reactions and LMIT provide better assessments of cell-mediated immunity post-vaccination.
Abstract